ArticlePLOS global public health2026
Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
Abstract
Controlled Human Infection Models (CHIM) in which volunteers are experimentally exposed to pathogens are used to study pathogenesis and down select among treatment and vaccine candidates. Scientifically, CHIM studies are best conducted among at-risk populations in which the infection is endemic, and who are likely to benefit from new interventions tested. Ethically, the perspectives of these communities should be carefully considered in designing such research. CHIM studies are often conducted among healthy adults, but we wished to understand study participant's and community views on conducting CHIM studies in groups other than healthy adults, particularly people living with HIV (PLHIV). We also wished to explore community perceptions of a tuberculosis CHIM (TB CHIM), initially using Bacillus Calmette Guerin (BCG) as a safe intermediate step. We conducted fourteen focus group discussions (FGD) and eight in-depth interviews (IDI) among a wide range of stakeholders including participants, health workers, community advisory groups, religious leaders and medical opinion leaders in Malawi. Discussions and interviews were recorded, transcribed and analysed using thematic and framework analysis. Four themes were described in the data, showing engaged stakeholder acceptance of CHIM studies, and confidence in the research practice and motivation. In the specific examples discussed in this work at-risk populations specifically PLHIV and complex pathogens specifically TB-CHIM, there was concern for safety, proper consent and community consultation. In addition, cultural views on gender roles in Malawi, tissue sampling and residential stays for research study were discussed. Overall, there was support for CHIM among PLHIV, and CHIM working through a BCG CHIM towards safe TB CHIM in future. Appropriate safety caveats and regulatory measures were suggested. Advice on wide, public awareness campaign methods was offered to researchers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.